Page 127 - 《中国药房》2026年3期
P. 127

伏诺拉生治疗消化性溃疡和ESD术后溃疡安全性和有效性的伞

          形评价
                    Δ


                                          1 #
          朱青梅 ,时 敏 ,杨东亮 ,赵海霞 (1.新疆医科大学第一附属医院新疆药物临床研究重点实验室,乌鲁木齐
                          2
                 1*
                                  1
          830054;2.中国药科大学基础医学与临床药学学院,南京 211198)
          中图分类号  R975.2      文献标志码  A      文章编号  1001-0408(2026)03-0389-06
          DOI  10.6039/j.issn.1001-0408.2026.03.20

          摘  要  目的  分析伏诺拉生(VPZ)治疗消化性溃疡(PU)和内镜黏膜下剥离术(ESD)术后溃疡的安全性与有效性,为临床实践、
          医疗决策提供循证药学证据。方法  计算机检索中国知网、万方、维普、中国生物医学文献数据库、PubMed、Embase、Web of Science、
          the Cochrane Library等数据库,获取VPZ治疗PU和ESD术后溃疡相关的Meta分析/系统评价。由2名研究者独立进行文献筛选、
          数据提取、文献质量评估、文献重叠程度评估,采用伞形评价分析方法;当纳入的文献高度重叠时,对所有相关原始研究数据重新
          进行Meta分析。结果  共纳入17项Meta分析,质量从高质量到极低质量不等;所有涉及的结局指标,在纳入的相关Meta分析中
          均存在非常高的重叠水平(校正覆盖面积为22.22%~100%)。治疗ESD术后溃疡时,与质子泵抑制剂(PPI)比较,VPZ可显著提
          高 ESD 术后 4 周的溃疡愈合率[RR=1.27,95%CI(1.03,1.56),Z=2.21,P=0.027]和溃疡收缩率[MD=0.08,95%CI(0.00,0.16),
          Z=2.09,P=0.037],显著降低具有PU病史患者的溃疡复发率[RR=0.49,95%CI(0.32,0.73),Z=3.49,P=0.001];VPZ组延迟出血
          率较兰索拉唑亚组显著降低[RR=0.47,95%CI(0.25,0.90),Z=2.28,P=0.02]。治疗PU时,十二指肠溃疡亚组中,VPZ的不良事
          件发生率明显高于PPI[RR=1.13,95%CI(1.02,1.26),Z=2.38,P=0.017]。结论  对于ESD术后溃疡,VPZ的治疗效果优于PPI,且
          可以降低具有PU病史患者的溃疡复发率,但在治疗十二指肠溃疡的安全性方面并不具有优势。
          关键词 伏诺拉生;消化性溃疡;内镜黏膜下剥离术术后溃疡;Meta分析;伞形评价;安全性;有效性

          Umbrella  review  analysis  of  the  safety  and  efficacy  of  vonoprazan  in  the  treatment  of  peptic  ulcers  and
          post-ESD ulcers
                                2
                      1
                                                                 1
          ZHU Qingmei ,SHI Min ,YANG Dongliang ,ZHAO Haixia(1.  Xinjiang  Key  Laboratory  of  Clinical  Drug
                                                  1
          Research,  the  First  Affiliated  Hospital  of  Xinjiang  Medical  University,  Urumqi  830054,  China;2.  School  of
          Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China)
          ABSTRACT   OBJECTIVE  To  analyze  the  safety  and  efficacy  of  vonoprazan (VPZ)  in  the  treatment  of  peptic  ulcer (PU)  and
          post-endoscopic  submucosal  dissection (ESD)  ulcers,  providing  evidence-based  pharmaceutical  evidence  for  clinical  practice  and
          medical decision-making. METHODS Retrieved from CNKI, Wanfang, VIP, CBM, PubMed, Embase, Web of Science, and the
          Cochrane Library, meta-analyses/systematic reviews related to VPZ in the treatment of PU and post-ESD ulcers were collected. Two
          researchers independently performed literature screening, data extraction, quality assessment of included studies, and evaluation of
          literature overlap. By employing the umbrella review analysis, a fresh meta-analysis was conducted on all relevant raw research data
          when  a  high  degree  of  overlap  was  identified  among  the  included  studies.  RESULTS  A  total  of  17  meta-analyses  were  included,
          with  quality  ranging  from  high  to  very  low;  all  outcome  measures  involved  showed  a  very  high  level  of  overlap  in  the  included
          meta-analyses (corrected  covered  area:  22.22%-100%).  In  the  treatment  of  post-ESD  ulcers,  compared  to  proton  pump  inhibitor
         (PPI),  VPZ  significantly  improved  the  ulcer  healing  rate  at  4  weeks  post-ESD  [RR=1.27,  95%CI (1.03,  1.56),  Z=2.21,  P=
          0.027]  and  the  ulcer  contraction  rate  post-ESD  [MD=0.08,  95%CI (0.00,  0.16),  Z=2.09,  P=0.037],  while  significantly
          reducing  the  ulcer  recurrence  rate  in  patients  with  a  history  of  PU  [RR=0.49,  95%CI (0.32,  0.73),  Z=3.49,  P=0.001];  the
                                                             delayed bleeding rate in the VPZ group was significantly lower
                                                             than  that  in  the  lansoprazole  subgroup  [RR=0.47,  95%CI
             Δ 基金项目“天山英才”医药卫生高层次人才培养计划(No.
          TSYC202301B154);新疆药物临床研究重点实验室开放课题(No.             (0.25, 0.90), Z=2.28, P=0.02]. In the treatment of PU, the
          2024XJYWY07);新疆维吾尔自治区药学会科研基金资助项目(No.               incidence  of  adverse  events  with  VPZ  was  significantly  higher
          YXH202413)                                         than  that  with  PPI  in  the  duodenal  ulcer  subgroup  [RR=1.13,
             *第一作者 主管药师,硕士。研究方向:临床药学。E-mail:                 95%CI (1.02,  1.26),  Z=2.38,  P=0.017].  CONCLUSIONS
          zhuqingmei111@126.com
             # 通信作者 主管药师,硕士。研究方向:临床药学。E-mail:                For  post-ESD  ulcers,  VPZ  demonstrates  superior  therapeutic
          979401278@qq.com                                   efficacy compared to PPI and can reduce ulcer recurrence rates


          中国药房  2026年第37卷第3期                                                 China Pharmacy  2026 Vol. 37  No. 3    · 389 ·
   122   123   124   125   126   127   128   129   130   131   132